Overview

Ferinject® Assessment in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF)

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy of Ferinject® in improving symptoms of CHF in patients with iron deficiency. Analyses will focus both on subjective and objective measures. Furthermore, the tolerability and safety of Ferinject® treatment will be evaluated.
Phase:
Phase 3
Details
Lead Sponsor:
Vifor Inc.
Vifor Pharma
Collaborators:
ClinStar, LLC
INC Research
Syneos Health
Treatments:
Ferric Compounds
Iron